SCHEMBL606776

SCHEMBL606776

CC1CN(CC(O)Cn2c3ccccc3c3cc(Cl)ccc32)CC(C)N1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAD52 P43351 3/20 0.57
NLRP1 Q9C000 1/20 0.57
MEN1 O00255 4/20 0.54
KMT2A Q03164 4/20 0.54
PER2 O15055 2/20 0.53
ALDH1A1 P00352 2/20 0.52
HTT P42858 2/20 0.52
KDM4E B2RXH2 2/20 0.52
LMNA P02545 2/20 0.52
MAPT P10636 1/20 0.52
SIGMAR1 Q99720 2/20 0.50
TP53 P04637 1/20 0.50
CYP1A2 P05177 1/20 0.50
CYP3A4 P08684 1/20 0.50
CYP2D6 P10635 1/20 0.50
CYP2C9 P11712 1/20 0.50
ALOX15 P16050 1/20 0.50
TSHR P16473 1/20 0.50
HTR2A P28223 1/20 0.50
HTR2C P28335 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6819364 0.83 RAD52 (0.76) RAD52NLRP1MEN1KMT2AALDH1A1
SCHEMBL6816191 0.83 RAD52 (0.76) RAD52NLRP1MEN1KMT2AALDH1A1
SCHEMBL1306615 0.81 MEN1 (0.70) RAD52NLRP1MEN1KMT2AALDH1A1
SCHEMBL609624 0.80 RAD52 (0.51) RAD52NLRP1MEN1KMT2APER2
SCHEMBL607619 0.77 LMNA (0.81) RAD52NLRP1MEN1KMT2AALDH1A1
SCHEMBL5024381 0.77 RAD52 (0.47) RAD52NLRP1MEN1KMT2APER2
SCHEMBL6823233 0.76 RAD52 (0.86) RAD52NLRP1MEN1KMT2AALDH1A1
SCHEMBL28589907 0.76 RAD52 (0.72) RAD52NLRP1MEN1KMT2APER2
SCHEMBL16604024 0.76 RAD52 (0.74) RAD52NLRP1MEN1KMT2AALDH1A1
SCHEMBL5024337 0.76 RAD52 (0.57) RAD52NLRP1MEN1KMT2APER2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1237887-B1 9-(PIPERAZINYLALKYL)CARBAZOLES AS BAX-MODULATORS SERONO LAB (CH) 2008-06-04 EP claimed
EP-1237887-A1 9-(PIPERAZINYLALKYL)CARBAZOLES AS BAX-MODULATORS Applied Research Systems ARS Holding N.V. (AN) 2002-09-11 EP claimed
WO-2001029028-A1 9- (PIPERAZINYLALKYL) CARBAZOLES AS BAX-MODULATORS APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) 2001-04-26 WO claimed
US-8410110-B2 9-(piperazinylalkyl) carbazoles as Bax-modulators MERCK SERONO SA (CH) 2013-04-02 US disclosed
US-20120040933-A1 9-(PIPERAZINYLALKYL) CARBAZOLES AS BAX-MODULATORS APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) 2012-02-16 US disclosed
US-8053436-B1 9-(piperazinylalkyl) carbazoles as bax-modulators MERCK SERONO SA (CH) 2011-11-08 US disclosed
EP-1237887-B1 9-(PIPERAZINYLALKYL)CARBAZOLES AS BAX-MODULATORS SERONO LAB (CH) 2008-06-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120040933-A1 9-(PIPERAZINYLALKYL) CARBAZOLES AS BAX-MODULATORS BCL2, BAX, BAD RAD52 3656/4885NLRP1 2445/4885MEN1 3810/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.